Citius Pharmaceuticals announced that the U.S. FDA has accepted the resubmission of the company’s Biologics License Application for LYMPHIR, an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The FDA has assigned a PDUFA goal date of August 13, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTXR:
- Citius Pharmaceuticals files $250M mixed securities shelf
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals Resubmits LYMPHIR™ License Application
- Citius announces resubmission of BLA to FDA forLYMPHIR
Questions or Comments about the article? Write to editor@tipranks.com